Shares of Akero are up $6.05, or 16%, to $44.19 following the blog report claiming that the company has hired an investment bank and is exploring a potential sale after being approached by a strategic buyer about a takeover.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics exploring potential sale after approach, Street Insider says
- Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
- Akero Therapeutics price target lowered to $78 from $80 at Citi
- Akero Therapeutics Advances in MASH Treatment Research
- Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley